If you have been reading about 稳定性 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-01-31. Where a claim depends on a specific study, the study is described rather than over-claimed.
Tesamorelin acts on the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in intracellular cyclic AMP, which in turn opens ion channels and raises calcium concentrations, leading to release of stored growth hormone into the bloodstream. Because the peptide works through the same receptor as the body's own GHRH, the resulting secretion follows a pulsatile pattern rather than a continuous elevation. The N-terminal modification slows enzymatic breakdown, so the signal persists longer than it would with the unmodified hormone.
Growth hormone released from the pituitary stimulates the liver and other tissues to produce insulin-like growth factor 1, a stable circulating protein that serves as a practical marker of activity. Clinical studies therefore track IGF-1 concentrations alongside the hormone itself, and they commonly measure body composition with imaging rather than relying on body weight alone. Visceral adipose tissue, the fat surrounding abdominal organs, is quantified by computed tomography in the studies that supported approval. Adverse effects reported in trials include injection-site reactions, joint pain, and increases in blood glucose, which is why monitoring accompanies use.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, composed of 44 amino acids. It was designed to retain the biological activity of the native hormone while resisting rapid enzymatic degradation. The compound is classified as a growth hormone secretagogue and belongs to the broader family of hypothalamic releasing factors. In research and clinical settings, it is studied for its ability to stimulate pituitary growth hormone release. Its structure includes a modification at the N-terminus that contributes to an extended half-life relative to native growth hormone-releasing hormone.
Tesamorelin binds to growth hormone-releasing hormone receptors on the surface of pituitary somatotroph cells. This binding activates adenylate cyclase, raising intracellular cyclic AMP levels and triggering the release of growth hormone into circulation. The elevated growth hormone then stimulates hepatic production of insulin-like growth factor 1. Because the effect is mediated through the endogenous axis, secretion remains subject to feedback regulation. This distinguishes it from direct growth hormone administration, which bypasses pituitary control entirely.
Clinical investigation has focused on HIV-associated lipodystrophy, a condition in which antiretroviral therapy contributes to abnormal fat distribution. Excess visceral adipose tissue accumulates in the abdomen while peripheral fat may be lost. Tesamorelin was evaluated for reducing this visceral fat depot, with trials measuring changes in abdominal fat by imaging rather than by body weight alone. The rationale rests on the known lipolytic effects of growth hormone. Effects on visceral fat are documented, while long-term outcomes regarding cardiovascular risk remain less clearly established.
| Property | Value | Notes |
|---|---|---|
| Receptor target | Growth hormone-releasing hormone receptor | G-protein-coupled receptor expressed on pituitary somatotroph cells |
| Primary signaling route | Cyclic AMP and protein kinase A | Increases intracellular calcium and promotes hormone release |
| Downstream marker | Insulin-like growth factor 1 | Blood concentration used as an integrated activity indicator |
| Study endpoint | Change in visceral adipose tissue | Assessed with computed tomography in trial populations |
| Research status | Investigational outside the approved indication | Trials in cognitive impairment did not meet primary endpoints |
Identity and purity are judged through a combination of chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the intact peptide from truncated, oxidized, and deamidated variants, and the resulting peak-area percentages yield a purity figure. Electrospray ionization mass spectrometry confirms the expected molecular mass and can expose unanticipated modifications. Amino acid analysis and peptide mapping support sequence fidelity, while water content, pH, sterility, and bacterial endotoxin testing describe the physical and microbiological attributes of a finished lot.
Regulatory position depends on jurisdiction and on the form in which the material is sold. A branded product holds approval in the United States for a defined indication, and prescribing is confined to that label. Material marketed for laboratory research is not evaluated for human use and carries no such clearance. Independent verification therefore rests on certificates of analysis, third-party testing, and documented chain of custody. The substance also appears on the World Anti-Doping Agency prohibited list within the category covering growth hormone-releasing factors.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, built from 44 amino acids. Its sequence follows the natural human GHRH(1-44) backbone, with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification blocks recognition by dipeptidyl peptidase IV, the enzyme that rapidly truncates the native hormone in circulation. The result is a molecule with a substantially longer plasma residence time than unmodified GHRH, which makes it practical for clinical and laboratory study.
Receptor-level activity begins when the peptide binds the GHRH receptor, a class B G-protein-coupled receptor found on pituitary somatotroph cells. Occupancy triggers Gs-mediated activation of adenylyl cyclase and a rise in intracellular cyclic AMP, which in turn promotes synthesis and pulsatile release of growth hormone. Because the compound acts upstream of the growth hormone axis rather than supplying hormone directly, its effect depends on intact pituitary function. Binding studies in cell culture and animal models have established this pathway; the detailed kinetics of receptor recycling in humans remain less well characterized.
Physicochemical behavior is dominated by the peptide backbone. The molecule is hydrophilic and carries a net positive charge near neutral pH, owing to several arginine and lysine residues. In solution it adopts a largely unstructured conformation, and aggregation is a known concern for peptide products of this size. Oxidation of methionine and deamidation of asparagine or glutamine residues are the principal chemical degradation routes. These liabilities shape how the material is formulated, handled, and analyzed, and they explain why lyophilized presentations are common in research settings.
冻干粉末一般在 -20°C 或更低温度、干燥避光条件下保存，可维持较长时间的稳定。复溶后稳定性明显下降，溶液中的肽链易发生水解、氧化与聚集，通常需冷藏并在短期内用完。反复冻融会加速聚集与降解，建议分装后单次使用。缓冲体系的 pH 与离子强度同样影响聚集速率，需要按具体实验条件验证。
研究用与临床用材料的标准并不相同。质量控制通常覆盖纯度、残留溶剂、反离子含量、微生物限度与内毒素水平，各项均有对应检测方法。随货文件应包含批号、检测项目、方法与结果，使数据可以追溯。核验时应关注纯度是否按主峰面积计算、杂质是否已定性、方法是否经过验证，这些信息决定结果能否被外部重复。
纯度与身份确认依赖色谱与质谱的组合。反相高效液相色谱在 214 nm 紫外检测下分离主峰与相关杂质，给出纯度百分比与保留时间；电喷雾或基质辅助激光解吸电离质谱提供分子量，用于确认 N 端修饰是否完整。序列层面可通过肽图或氨基酸分析验证。含量测定常用紫外吸收法或氮元素分析，不同方法之间需要做交叉校验。
Interest in this peptide developed because native GHRH has a short circulating lifetime. The N-terminal modification slows cleavage by dipeptidyl peptidase IV, an enzyme that removes the first two residues of many peptides and terminates their activity. Slower degradation means a longer window of receptor stimulation per administration. This design logic parallels other modified peptide hormones, where a small chemical change at a vulnerable site yields a more durable molecule without altering the core mechanism of action.
The peptide is synthesized chemically rather than extracted from biological sources. Solid-phase synthesis builds the chain from the C-terminus toward the N-terminus, after which the hexenoyl group is attached. Purity is typically assessed by high-performance liquid chromatography, and identity is confirmed by mass spectrometry. Regulatory review of the finished product focuses on these analytical controls, since small deviations in sequence or modification can change biological activity. Questions about long-term effects on the pituitary axis remain areas of continued investigation.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone (GHRH) family. Its sequence corresponds to the fully active 44-amino-acid form of human GHRH, with a single structural modification: the addition of a trans-3-hexenoyl group at the N-terminus. That modification is not found in the naturally occurring hormone and was introduced deliberately during development to improve stability against enzymatic degradation. The compound is therefore best described as a stabilized analogue rather than a naturally occurring peptide.
Fimbrian legions: 86 BC – 66 BC, Lucius Valerius Flaccus. These two legions fought in the Mithridatic Wars. Legio I Germanica (Germanic): 48 BC – AD 70 (Revolt of the Batavi), Julius Caesar (emblem: bull) Legio II Sabina (Sabine): 43 BC – 4th century AD, early name of the Legio II Augusta, Octavian Legio III Cyrenaica (from Cyrene): probably c. 36 BC to (at least) the 5th century, Mark Antony Legio III Gallica (Gallic): around 49 BC to at least early 4th century, Julius Caesar (emblem: bull) Legio IV Macedonica (Macedonian): 48 BC – AD 70 (renamed by Vespasian), Julius Caesar (emblem: bull, capricorn) Legio IV Scythica (from Scythia): c.
=== Defense against pathogens === The exposure to these reactive species in the respiratory burst results in pathology. This is due to oxidative damage to the engulfed bacteria. Notably, peroxynitrite is a very strong oxidising agent that can lead to lipid peroxidation, protein oxidation, protein nitration, which are responsible for its bactericidal effects. It may react directly with proteins that contain transition metal centers, such as FeS, releasing Fe2+ for the Fenton reaction. Peroxynitrite may also react with various amino acids in the peptide chain, thereby altering protein structure and subsequently, protein function. It most commonly oxidises cysteine, and may indirectly induce tyrosine nitration through other generated RNS. Altered protein function includes changes in enzyme catalytic activity, cytoskeletal organisation and cell signal transduction. Hypochlorous acid reacts with a range of biomolecules, including DNA, lipids and proteins. HClO may oxidise cysteines and methionines via their sulfhydryl groups and sulfur groups respectively. The former leads to the formation of disulfide bonds, inducing protein crosslinking. Both oxidations result in protein aggregation, and ultimately, cell death. Sulfhydryl groups can be oxidised up to three times by three HClO molecules, forming sulfenic acids, sulfinic acids and R–SO3H, which are increasingly irreversible and bactericidal. Meanwhile, methionine oxidation is reversible. HOCl can also react with primary or secondary amines, producing chloroamines which are toxic to bacteria.
==== Dopamine ==== In certain brain regions, amphetamine increases the concentration of dopamine in the synaptic cleft by modulating DAT through several overlapping processes. Amphetamine can enter the presynaptic neuron either through DAT or, to a lesser extent, by diffusing across the neuronal membrane directly. As a consequence of DAT uptake, amphetamine produces competitive reuptake inhibition at the transporter. Upon entering the presynaptic neuron, amphetamine provokes the release of Ca2+ from endoplasmic reticulum stores, an effect that raises intracellular calcium to levels sufficient for downstream kinase-dependent signalling. In parallel, amphetamine also increases intracellular cAMPTooltip cyclic adenosine monophosphate, which activates protein kinase A (PKA) and protein kinase C (PKC), whilst elevated intracellular Ca2+ activates PKC alone. Phosphorylation of DAT by either kinase induces transporter internalization (non-competitive reuptake inhibition), but PKC-mediated phosphorylation alone induces the reversal of dopamine transport through DAT (i.e., dopamine efflux). TAAR1 has been identified as a biomolecular target of amphetamine that initiates some of amphetamine's kinase-dependent signaling cascades. When TAAR1 signals via Gs-coupled receptors, intracellular cAMP increases through adenylyl cyclase activation and activates PKA and PKC, in turn phosphorylating DAT.
Sources: en.wikipedia.org
A variety of contractors are involved in the production, management, and distribution of UGRs and their contents, including (as of 2023) ABC Ventures, AmeriQual, Atlantic, Chef Minute Meals, Club Tex, Envision, Inc., Epic Foods, Gossner Foods, Hershey, HOIST, LC Industries, Nex-Xos, OhSix, Oregon Freeze Dry, Sterling Foods, Sopakco, Valley Foods, Werling Meats, and Wornick. More than 60,000 UGRs are produced each year. UGRs are supplied by the DLA's Operational Rations Division. UGRs, like other rations, cannot be sold to individuals, and are only supplied or sold to the U.S. military, the DoD, the federal government, government employee commissaries, government contractors (if their contract specifically permits such purchases), foreign governments with authorized contractual relationships, and civilians as humanitarian aid.
Communication delays during the crisis led to the establishment of the Moscow–Washington hotline to allow reliable, direct communications between the two nuclear powers. By the late 1960s, the number of ICBMs and warheads was so high on both sides that it was believed that both the United States and the Soviet Union were capable of completely destroying the infrastructure and a large proportion of the population of the other country. Thus, by some western game theorists, a balance of power system known as mutually assured destruction (or MAD) came into being. It was thought that no full-scale exchange between the powers would result in an outright winner, with at best one side emerging the pyrrhic victor. Thus both sides were deterred from risking the initiation of a direct confrontation, instead being forced to engage in lower-intensity proxy wars. During this decade the People's Republic of China began to build subterranean infrastructure such as the Underground Project 131 following the Sino-Soviet split. One drawback of the MAD doctrine was the possibility of a nuclear war occurring without either side intentionally striking first. Early Warning Systems (EWS) were notoriously error-prone. For example, on 78 occasions in 1979 alone, a "missile display conference" was called to evaluate detections that were "potentially threatening to the North American continent". Some of these were trivial errors and were spotted quickly, but several went to more serious levels.
=== Notch signaling === In 2015 and 2017, Garcia published articles in Science describing the first atomic-level visualizations of Notch signaling complexes. Garcia's group used directed evolution to strengthen low-affinity interactions between the receptor Notch1 and ligands Delta-like 4 (DLL4) and Jagged1 (Jag1) as a means of stabilizing the complexes for co-crystallization. Notch1-DLL4 and Notch1-Jag1 structures were determined by x-ray crystallography and revealed long, narrow binding interfaces assisted by multiple O-linked fucose and glucose modifications on Notch1. O-linked glycans are rarely observed at protein-protein interfaces, and their presence at the Notch-ligand interface explained how changes in glycosylation state influence Notch signaling activity. Garcia's 2017 publication also established that Notch-ligand interactions form catch bonds, and that Delta-like and Jagged ligands have different mechanical force thresholds for Notch receptor activation.
A gonadotropin-releasing hormone antagonist (GnRH antagonist) is a GnRH modulator that blocks the GnRH receptor resulting in an immediate drop in gonadotropin (FSH, LH) secretion. GnRH antagonists are primarily used in IVF treatments to block natural ovulation.
Sources: en.wikipedia.org
The three substrates of this enzyme are D-erythrose 4-phosphate, oxidised nicotinamide adenine dinucleotide (NAD+), and water. Its products are 4-phospho-D-erythronic acid, reduced NADH, and a proton. This enzyme belongs to the family of oxidoreductases, specifically those acting on the aldehyde or oxo group of donor with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is D-erythrose 4-phosphate:NAD+ oxidoreductase. Other names in common use include erythrose 4-phosphate dehydrogenase, E4PDH, GapB, Epd dehydrogenase, and E4P dehydrogenase. This enzyme participates in vitamin B6 metabolism (see DXP-dependent biosynthesis of pyridoxal phosphate).
Colin Ayton Greenhalgh, Principal, Hills Road Sixth Form College, Cambridge. For services to Education. Ian Gregg, Chairman, River Tweed Commissioners and Tweed Foundation. For services to Salmon and Trout Fishing. Vernon Charles Grove, Administrator, Wales and Chester Circuit, Lord Chancellor's Department. Rex Farrow Gyngell, . For political and public service. Arthur Barry Haines, Chair, Aerodynamics Group, Royal Aeronautical Society. For services to Aerodynamics. Eunice Hanna. For political service. Lieutenant Colonel Grattan Herbert Hart, . For services to the Royal British Legion in Sussex. Robert James Hasson, Assistant Controller (Collection and Personnel), Board of Inland Revenue. Anthony Roger Heath. For services to the Administration of Justice. Jennifer Mary Toresen, Lady Hemingford. For services to the community in Hemingford Abbots, Cambridgeshire and to the British Red Cross Society. Desmond Charles Henley, Embalmer. For services in the Aftermath of Disasters. Damon Graham Hill. For services to Motor Racing. John William Hoaen, Grade 7, Department of Trade and Industry. Margaret Edith Hobrough, Principal and Chief Executive, Godalming Sixth Form College, Surrey. For services to Education. Brigadier David Hendry Hodge, . For services to the Territorial Auxiliary and Volunteer Reserve Association in the North of England. The Reverend Roger Graham Holloway. For services to Export. John Hood. For services to Industry. John Trevor Hopkins, Headmaster, Bishop Stopford School, Kettering, Northamptonshire. For services to Education.
=== Menstrual disturbances === Spironolactone at higher doses can cause menstrual irregularities as a side effect in women, including metrorrhagia (intermenstrual bleeding), amenorrhea (absence of menstruation), and breakthrough bleeding. They are common during spironolactone therapy, with 10 to 50% of women experiencing them at moderate doses and almost all experiencing them at a high doses. For example, about 20% of women experienced menstrual irregularities with 50 to 100 mg/day spironolactone, whereas about 70% experienced menstrual irregularities at 200 mg/day. Most women taking moderate doses of spironolactone develop amenorrhea, and normal menstruation usually returns within two months of discontinuation. Spironolactone produces an irregular and anovulatory pattern of menstrual cycles. It is also associated with metrorrhagia and menorrhagia (heavy menstrual bleeding) in large percentages of women, as well as with polymenorrhea (short menstrual cycles). The medication reportedly has no birth control effect. The weak progestogenic activity of spironolactone has been suggested to be responsible for these effects, although not established, and spironolactone has been shown to possess insignificant progestogenic and antiprogestogenic activity even at high dosages in women. An alternative proposed cause is inhibition of 17α-hydroxylase and hence sex steroid metabolism by spironolactone and consequent changes in sex hormone levels. Indeed, CYP17A1 genotype is associated with polymenorrhea.
Sources: en.wikipedia.org
It acts upstream at the pituitary receptor and depends on functioning somatotroph cells to produce any effect. Growth hormone injections bypass that step and deliver the hormone directly. The pharmacokinetic profiles and the resulting feedback on the body's own secretion therefore differ.
Insulin-like growth factor 1 is a downstream product of growth hormone action and changes more slowly than the hormone itself. Its blood concentration is used as an integrated indicator of whether the pathway has been stimulated. Interpretation requires attention to nutrition, illness, and other factors that shift IGF-1 independently.
No. The approved indication concerns excess visceral abdominal fat in adults with HIV infection and lipodystrophy, a specific clinical population. It is not cleared for general weight reduction or for cosmetic use. Studies in other groups remain investigational.
It is a synthetic analog of growth hormone-releasing hormone, a hypothalamic peptide. It functions as a growth hormone secretagogue acting at pituitary receptors. The classification separates it from direct growth hormone products.